Stoneridge Investment Partners LLC Invests $2.13 Million in Baxter International Inc. $BAX

Stoneridge Investment Partners LLC bought a new position in Baxter International Inc. (NYSE:BAX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 93,458 shares of the medical instruments supplier’s stock, valued at approximately $2,128,000. Baxter International accounts for approximately 1.5% of Stoneridge Investment Partners LLC’s holdings, making the stock its 16th biggest position.

Other institutional investors have also recently added to or reduced their stakes in the company. Dodge & Cox increased its stake in Baxter International by 1.3% during the second quarter. Dodge & Cox now owns 52,121,620 shares of the medical instruments supplier’s stock worth $1,578,243,000 after acquiring an additional 662,695 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Baxter International by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 12,882,960 shares of the medical instruments supplier’s stock valued at $388,416,000 after purchasing an additional 326,652 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Baxter International by 1.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock worth $231,304,000 after purchasing an additional 97,687 shares during the period. Russell Investments Group Ltd. increased its position in Baxter International by 13.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,900,828 shares of the medical instruments supplier’s stock worth $57,568,000 after purchasing an additional 224,804 shares in the last quarter. Finally, Cooke & Bieler LP raised its holdings in Baxter International by 10.8% in the second quarter. Cooke & Bieler LP now owns 1,750,510 shares of the medical instruments supplier’s stock valued at $53,005,000 after buying an additional 170,560 shares during the period. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International News Roundup

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Zacks Research nudged some forward estimates up — small raises to Q3 2027 and FY2027 EPS expectations (Q3 2027 to $0.71; FY2027 to $2.50) could be read as modestly constructive for long‑term earnings visibility. Zacks Research estimate update
• Neutral Sentiment: Baxter announced a conference call to present fourth‑quarter 2025 financial results — this is a standard investor event but is a near‑term catalyst where management can clarify outlook, margins and cost actions. Baxter to Host Fourth-Quarter 2025 Financial Results Conference Call for Investors
• Neutral Sentiment: MarketWatch notes Baxter has underperformed peers despite some daily gains — highlights relative weakness that may keep investor caution elevated until clearer earnings/strategy signals appear. MarketWatch performance note
• Negative Sentiment: Zacks Research downgraded Baxter to a “Strong Sell” and cut several near‑term EPS forecasts (reductions to Q3/Q4 2026 and FY2026 estimates reported), signaling weaker near‑term profit expectations and exerting downward pressure on sentiment. Zacks downgrade and estimate cuts
• Negative Sentiment: Brokerage consensus has shifted toward “Reduce”/“Reduce”‑type recommendations (average recommendation reported as “Reduce”), reflecting broad sell‑side caution that can increase selling pressure and weigh on the stock until clearer positive catalysts emerge. Average recommendation “Reduce”

Analyst Ratings Changes

Several research firms have issued reports on BAX. Wells Fargo & Company decreased their price objective on shares of Baxter International from $21.00 to $19.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Wall Street Zen raised shares of Baxter International from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Citigroup decreased their price target on shares of Baxter International from $26.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, October 31st. Stifel Nicolaus lowered their price target on Baxter International from $25.00 to $22.00 in a report on Friday, October 31st. Finally, Morgan Stanley cut their price objective on Baxter International from $19.00 to $15.00 and set an “underweight” rating on the stock in a research report on Tuesday, December 2nd. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $21.40.

Baxter International Price Performance

Shares of BAX stock opened at $19.84 on Friday. The firm has a fifty day simple moving average of $19.18 and a 200-day simple moving average of $22.05. The company has a market capitalization of $10.20 billion, a PE ratio of -30.05, a price-to-earnings-growth ratio of 1.16 and a beta of 0.59. Baxter International Inc. has a twelve month low of $17.40 and a twelve month high of $37.74. The company has a current ratio of 1.84, a quick ratio of 1.18 and a debt-to-equity ratio of 1.21.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, October 30th. The medical instruments supplier reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.09. The firm had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.88 billion. Baxter International had a negative net margin of 3.09% and a positive return on equity of 17.38%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.80 EPS. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS. Equities research analysts anticipate that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Friday, November 28th were issued a $0.01 dividend. The ex-dividend date of this dividend was Friday, November 28th. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. Baxter International’s dividend payout ratio is currently -6.06%.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.